Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 2Urothelial Cancer 1Solid Tumors, KRAS Mutation 1Prostatic Neoplasms 1Prostate Cancer Metastatic 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1KRAS p.G12C Mutant Advanced Solid Tumors 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Rituximab 5Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Cytarabine 4Busulfan 4Azacitidine 4AP 1903 reagent 4venetoclax 3ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Etoposide 3pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × Midazolam × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡